Yann Mazabraud - 16 Feb 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of International
Signature
/s/ Hunter Smith, Attorney-in-Fact for Yann Mazabraud
Issuer symbol
RYTM
Transactions as of
16 Feb 2024
Transactions value $
$0
Form type
4
Filing time
21 Feb 2024, 19:02:56 UTC
Previous filing
13 Feb 2024
Next filing
19 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Award $0 +33.8K +500.37% $0.00 40.5K 16 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Award $0 +22K $0.00 22K 16 Feb 2024 Common Stock 22K Direct F2, F3
transaction RYTM Stock Option (Right to Buy) Award $0 +67K $0.00 67K 16 Feb 2024 Common Stock 67K $49.23 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F3 The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date.
F4 The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.